Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2024-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Solicitation of Proxy Statement), which is a formal regulatory filing used by a company to request that shareholders grant them proxy voting rights for an upcoming General Meeting. This document provides details on the meeting agenda, the solicitation period, and methods for electronic or written voting. It falls under the category of Proxy Solicitation & Information Statement (PSI).
2024-03-14 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the board resolution, exercise price, vesting period, and individual allocation details for executives. Since this is a specific regulatory disclosure regarding capital structure and equity-based compensation, and does not fit into the other specific categories like 'Director's Dealing' (which is for trades) or 'Remuneration' (which is for compensation reports), it is classified as a Regulatory Filing (RNS).
2024-03-13 Korean
불성실공시법인지정 (공시번복)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory announcement from the Korea Exchange regarding the designation of 'Cellumed' as an unfaithful disclosure corporation due to a disclosure reversal (cancellation of bond issuance). This is a formal regulatory notice concerning compliance and penalties, which does not fit into specific categories like financial reports or shareholder meetings. Therefore, it falls under the general regulatory filing category.
2024-03-12 Korean
주식등의대량보유상황보고서(약식)
Regulatory Filings Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the acquisition of shares or convertible securities by Sangsangin Savings Bank and its affiliate in Cellumed. This type of filing is a mandatory regulatory disclosure regarding significant ownership thresholds and does not fit into specific categories like earnings releases, annual reports, or board changes. Therefore, it is classified as a Regulatory Filing (RNS).
2024-03-08 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Cellumed. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-03-07 Korean
전환가액의조정 (제25회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the company 'Cellumed' regarding the adjustment of the conversion price for its 25th series convertible bonds. This type of filing, which details changes to capital structure instruments (convertible debt), falls under the 'Capital/Financing Update' category. It is not a report publication announcement, but rather the primary disclosure of the financial adjustment itself.
2024-03-04 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.